期刊文献+

Ⅱ型人多巴胺受体逆转录病毒载体的构建及表达

RECONSTRUCTION AND EXPRESSION OF RETROVIRUS VECTOR WITH HUMAN D_2 RECEPTOR GENE
下载PDF
导出
摘要 目的构建人全长D2R基因真核表达载体,研究D2R在帕金森病(PD)中的作用和机制。方法将D2RcDNA片段克隆于pLNCX2逆转录病毒载体,转染成纤维包装细胞系PT67,G418筛选单克隆后进行传代培养,通过原位杂交、免疫组织化学和Westernblot检测其表达效果。病毒上清再感染骨髓基质细胞(MSCs),免疫荧光检测D2R基因表达率。结果成功构建了逆转录病毒表达载体pLNCX2_D2R,原位杂交证实D2R基因在PT_67表达的阳性率为80%以上,免疫组织化学检测可见其蛋白分布在胞浆和胞膜,细胞裂解后Westernblot蛋白电泳可检测到约48·84kD的蛋白。经转染D2R基因的PT67细胞能分泌病毒并感染MSCs。结论逆转录病毒介导的D2R基因经PT67细胞包装后,能够产生病毒颗粒,收集含病毒颗粒的上清可进一步感染MSCs,这种经逆转录病毒介导的DR基因可用来作针对帕金森病进行基因治疗的研究。 Objective To construct the eukaryotic expression vector of human full-length D2 receptor gene for further study on role in PD. Methods cDNA fragment of D2 receptor was subcloned into retrovirus vector pLNCX2 which was used to transfected into the PT67 cell line. Cell clones were obtained through G418 selection with passage. D2R gene expression was detected with in situ hybridization, immunocytochemistry and Western blot assay. The packaging cell medium containing virus particles was collected and infected bone marrow stromal cells(MSCs) and the efficiency was measured with immunofluorescence. Results The retrovirus vector pLNCX2-D2R was constructed successfully. More than 80% PT67 cells expressed the target gene. Porteins were detected in plasm and cell membrane was lysed and proteins were harvested for Western blot assays. A fragment of 48.84kD length was manifested with Western blot. Virus particles were secreted from PT-67 cells and were used to further infect MSCs. Conclusion The cloned human D2 receptor gene was expressed in PT67 cells and MSCs was efficiently infected by the recombinant retrovirns, pLNCX2-D2 R could be used to delivery vehicle for gene therapy of PD.
出处 《解剖学报》 CAS CSCD 北大核心 2005年第4期356-360,共5页 Acta Anatomica Sinica
基金 北京市自然科学基金B类和北京市教委科技发展规划重点项目(KZ200310025009) 北京市自然科学基金资助项目(7022005)
关键词 多巴胺D2受体 帕金森病 基因治疗 原位杂交 Dopamine D2 receptor Parkinson disease Gene therapy In situ hybridization Human
  • 相关文献

参考文献15

  • 1Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors:an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine [ J].Am J Psychiatry, 1999,156(6) :876-884.
  • 2Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease [ J ]. Exp Neurol, 1997,144( 1 ) :4-9.
  • 3Hierholzer J, Cordes M, Venz S, et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes[ J]. J Nucl Med, 1998,39(6) :954-960.
  • 4Seeman P, Nam D, Ulpian C, et al. New dopamine receptor, D2(Longer), with unique TG splice site in human brain[J]. Brain Res Mol Brain Res,2000,76(1):132-141.
  • 5Khan ZU, Mrzljak L, Gutierrez A, et al. Prominence of the dopamine D2short isoform in dopaminergic pathways[J]. Proc Natl Acad Sci USA,1998,95(13) :7731-7736.
  • 6赵焕英,段德义,张智,徐群渊,杨慧.人胚胎脑多巴胺D_2受体基因的克隆[J].首都医科大学学报,2002,23(1):1-5. 被引量:2
  • 7Yang H, An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs [ J]. Histochem Cytochem, 1999,47 (4): 431-445.
  • 8Cox KH, Deleon DV, Angerer LM, et al. Detection of mRNAs in sea urchin embryos by in situ hybridization using asymmetric RNA probes [J]. Dev Biol, 1984,101 (2) :485-502.
  • 9Mochizuki H, Mizuno Y, Gene therapy for Parkinson's disease [ J ]. J Neural Transm,2003,65(Suppl) :205-213.
  • 10Kodama Y, Hida H, Jung CG, et al. High titer retroviral gene transduction to neural progenitor cells for establishment of donor cells for neural transplantation to parkinsonian model rats [ J ]. Neurol Med Chir ( Tokyo ), 2004,44 (7): 344-351.

二级参考文献14

  • 1[1]Emilien G,Maloteaux J M,Hoogenberg K,et al.Dopamine receptors-physiological understanding to therapeutic intervention potential.Pharmacol Ther,1999,84:133~56
  • 2[2]Elsworth J D,Roth R H.Dopamine syntesis,uptake,metabolism,and receptors:relevance to gene therapy of Parkinson's disease.Exp Neurol,1997,144:4~9
  • 3[3]Beaulieu M.Clinical importance of D1 and D2 receptors.Can J Neurol Sci,1987,14:402~406
  • 4[4]Turjanski N,Lees A J,Brooks D J.In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.Neurology,1997,49:717~723
  • 5[5]Hierholzer J,Cordes M,Venz S,et al.Loss of dopamine-D2 receptor binding sites in Parkinsonian Plus syndromes.J Nucl Med,1998,39:954~960
  • 6[6]Ryoo H L,Pierrotti D,Joyce J N.Dopamine D3 receptor is decreased and D2 receptor is elevated in striatum of Parkinson's disease.Mov Disord,1998,13:788~797
  • 7[7]Amenta F,Ricci A,Rossodivita I,Avola R,Tayebati S K.The dopaminergic system in hypertension.Clin Exp Hypertens,2001,23(1-2):15~24
  • 8[8]Picetti R,Saiardi A,Abdel Samad T,et al.Dopamine D2 receptors in signal transduction and behavior.Crit Rev Neurobiol,1997,11(2-3):121~142
  • 9[9]Liu I S C,George S R,Seeman P.The human dopamine D2 Longer receptor has a high-affinity state and inhibits adenylyl cyclase.Mol Brain Res,2000,77:281~284
  • 10[10]Senogles S E.The D2s dopamine receptor stimulates phospholipase D activity:a novel signaling pathway for dopamine.Mol Pharmacol,2000,58:455~462

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部